Nuvectis Pharma Net Worth
Nuvectis Pharma Net Worth Breakdown | NVCT |
Nuvectis Pharma Net Worth Analysis
Nuvectis Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nuvectis Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nuvectis Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nuvectis Pharma's net worth analysis. One common approach is to calculate Nuvectis Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nuvectis Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nuvectis Pharma's net worth. This approach calculates the present value of Nuvectis Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nuvectis Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nuvectis Pharma's net worth. This involves comparing Nuvectis Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nuvectis Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Nuvectis Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nuvectis Pharma's net worth research are outlined below:
| Nuvectis Pharma is way too risky over 90 days horizon | |
| Nuvectis Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvectis Pharma currently holds about 13.57 M in cash with (12.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Laidlaw Begins Coverage on Nuvectis Pharma |
Nuvectis Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nuvectis Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nuvectis Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Nuvectis Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nuvectis Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nuvectis Pharma backward and forwards among themselves. Nuvectis Pharma's institutional investor refers to the entity that pools money to purchase Nuvectis Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Oppenheimer & Co Inc | 2024-12-31 | 25 K | State Street Corp | 2024-12-31 | 22 K | Squarepoint Ops Llc | 2024-12-31 | 19.1 K | Two Sigma Investments Llc | 2024-12-31 | 18.6 K | Edmond De Rothschild Holding S.a. | 2024-12-31 | 15.2 K | Baxter Bros Inc | 2024-12-31 | 15 K | Nations Financial Group Inc | 2024-12-31 | 13.5 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 6.3 K | Point72 Asia (singapore) Pte. Ltd | 2024-12-31 | 4.5 K | Baldwin Brothers Inc | 2024-12-31 | 356 K | Vanguard Group Inc | 2024-12-31 | 325.3 K |
Follow Nuvectis Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 220.82 M.Market Cap |
|
Project Nuvectis Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.69) | (1.77) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | (1.96) | (2.05) |
When accessing Nuvectis Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Nuvectis Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nuvectis Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Nuvectis Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nuvectis Pharma. Check Nuvectis Pharma's Beneish M Score to see the likelihood of Nuvectis Pharma's management manipulating its earnings.
Evaluate Nuvectis Pharma's management efficiency
Nuvectis Pharma has return on total asset (ROA) of (0.6565) % which means that it has lost $0.6565 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7341) %, meaning that it created substantial loss on money invested by shareholders. Nuvectis Pharma's management efficiency ratios could be used to measure how well Nuvectis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2025. Return On Capital Employed is likely to drop to -1.77 in 2025. Change To Liabilities is likely to gain to about 5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 5.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.57 | 0.60 | |
| Tangible Book Value Per Share | 0.57 | 0.60 | |
| Enterprise Value Over EBITDA | (5.56) | (5.83) | |
| Price Book Value Ratio | 9.53 | 10.01 | |
| Enterprise Value Multiple | (5.56) | (5.83) | |
| Price Fair Value | 9.53 | 10.01 | |
| Enterprise Value | 74 M | 53.8 M |
Nuvectis Pharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvectis Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvectis Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nuvectis Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nuvectis Pharma Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of February 2025 Other Reports | ViewVerify | |
| 3rd of January 2025 Other Reports | ViewVerify |
Nuvectis Pharma Earnings per Share Projection vs Actual
Nuvectis Pharma Corporate Executives
Elected by the shareholders, the Nuvectis Pharma's board of directors comprises two types of representatives: Nuvectis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvectis. The board's role is to monitor Nuvectis Pharma's management team and ensure that shareholders' interests are well served. Nuvectis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvectis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shay Shemesh | Executive CoFounder | Profile | |
| Enrique Poradosu | Executive CoFounder | Profile |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.